EGFR and cholangiocarcinoma: Claperon A et al. found that the cotransplantation of CCA tumor cells with human liver myofibroblasts increases tumor incidence, size, and metastatic dissemination in vivo; this effect can be inhibited by the EGFR tyrosine kinase inhibitor gefitinib [23].